[1] MATZDORFF A,MEYER O,OSTERMANN H,et al.Immune thrombocytopenia-current diagnostics and therapy:recommendations of a joint working group of DGHO,ÖGHO,SGH,GPOH,and DGTI[J].Oncol Res Treat,2018,41(Suppl 5):1-30. [2] SALAMA A.Emerging drugs for immune thrombocytopenia(ITP)[J].Expert Opin Emerg Drugs,2017,22(1):27-38. [3] RODEGHIERO F,STASI R,GERNSHEIMER T,et al.Standardization of terminology,definitions and outcome criteria in immune thrombocytopenic Purpura of adults and children:report from an international working group[J].Blood,2009,113(11):2386-2393. [4] KAPUR R,EINARSDOTTIR H K,VIDARSSON G.IgG-effector functions:“the good,the bad and the ugly”[J].Immunol Lett,2014,160(2):139-144. [5] MA L,ZHANG W,HOU M X,et al.Analysis of sialic acid levels in Chinese intravenous immunoglobulins by high-performance liquid chromatography with fluorescence detection[J].Biomed Chromatogr,2019,33(4):e4452. [6] AUDIA S,BONNOTTE B.Emerging therapies in immune thrombocytopenia[J].J Clin Med,2021,10(5):1004. [7] LEONTYEV D,KATSMAN Y,BRANCH D R.Mouse background and IVIG dosage are critical in establishing the role of inhibitory Fcγ receptor for the amelioration of experimental ITP[J].Blood,2012,119(22):5261-5264. [8] SCHWAB I,MIHAI S,SEELING M,et al.Broad requirement for terminal sialic acid residues and FcγRIIB for the preventive and therapeutic activity of intravenous immunoglobulins in vivo[J].Eur J Immunol,2014,44(5):1444-1453. [9] SPYCHER M,MATOZAN K,MINNIG K,et al.In vitro comparison of the complement-scavenging capacity of different intravenous immunoglobulin preparations[J].Vox Sang,2009,97(4):348-354. [10] WASSERMAN R L,GARCIA D,GREENER B N,et al.Manufacturing process optimization of ADMA Biologics' intravenous immunoglobulin products,BIVIGAM® and ASCENIV™[J].Immunotherapy,2019,11(16):1423-1433. [11] MIKOLAJCZYK M G,CONCEPCION N F,WANG T,et al.Characterization of antibodies to capsular polysaccharide antigens of Haemophilus influenzae type b and Streptococcus pneumoniae in human immune globulin intravenous preparations[J].Clin Diagn Lab Immunol,2004,11(6):1158-1164. [12] ORANGE J S,DU W,FALSEY A R.Therapeutic immunoglobulin selected for high antibody titer to RSV also contains high antibody titers to other respiratory viruses[J].Front Immunol,2015,6:431. [13] PETER J G,CHAPEL H.Immunoglobulin replacement therapy for primary immunodeficiencies[J].Immunotherapy,2014,6(7):853-869. [14] TZEKOU A,FEHLINGS M G.Treatment of spinal cord injury with intravenous immunoglobulin G:preliminary evidence and future perspectives[J].J Clin Immunol,2014,34(Suppl 1):S132-S138. [15] FRAUGER E,GRASSI J,PRADEL V,et al.Use of intravenous immunoglobulins in clinical practice:data from three French University hospitals[J].Fundam Clin Pharmacol,2011,25(6):753-761. [16] EL-SHANAWANY T,JOLLES S.Intravenous immunoglobulin and autoimmune disease[J].Ann N Y Acad Sci,2007,1110:507-515. [17] SILLIMAN C C,DZIECIATKOWSKA M,MOORE E E,et al.Proteomic analyses of human plasma:Venus versus Mars[J].Transfusion,2012,52(2):417-424. [18] 谢勇,唐诗佳,王贺,等.四川省部分地区献血浆人群调查与分析[J].中国输血杂志,2015,28(3):307-308. [19] SUN P,ZHANG W,DU X,et al.Demographic characteristics and lifestyle habits of Chinese plasma donors:a multicenter study[J].Med Sci Monit,2021,27:e931471. [20] DESAI M K,BRINTON R D.Autoimmune disease in women:endocrine transition and risk across the lifespan[J].Front Endocrinol(Lausanne),2019,10:265. [21] HU C J,SONG G,HUANG W,et al.Identification of new autoantigens for primary biliary cirrhosis using human proteome microarrays[J].Mol Cell Proteomics,2012,11(9):669-680. [22] HU C J,HUANG W,CHEN H,et al.Autoantibody profiling on human proteome microarray for biomarker discovery in cerebrospinal fluid and sera of neuropsychiatric lupus[J].PLoS One,2015,10(5):e0126643. [23] ZHANG W,YUAN X,WANG Z K,et al.Study on the treatment of ITP mice with IVIG sourced from distinct sex-special plasma(DSP-IVIG)[J].Int J Mol Sci,2023,24(21):15993. [24] DUELLBERG C,HANNAPPEL A,KISTNER S,et al.Biochemical characterization of a new 10% IVIG preparation[IgG next generation(BT595)/yimmugo®]obtained from a manufacturing process preserving IgA/IgM potential of human plasma[J].Drugs R D,2023,23(3):245-255. [25] Arumugham V B,Rayi A.Intravenous Immunoglobulin(IVIG)[J/OL].(2020-07-04).https://www.researchgate.net/publication/344176256_Intravenous_Immunoglobulin_IVIG_-_StatPearls_-_NCBI_Bookshelf. [26] KLEIN S L,FLANAGAN K L.Sex differences in immune responses[J].Nat Rev Immunol,2016,16(10):626-638. [27] ZHU Y,CAI X L,LIU Y,et al.Serum albumin,but not bilirubin,is associated with diabetic chronic vascular complications in a Chinese type 2 diabetic population[J].Sci Rep,2019,9(1):12086. [28] LIU J,WANG Y,XIONG E M,et al.Role of the IgM fc receptor in immunity and tolerance[J].Front Immunol,2019,10:529. [29] ZHANG R,SHUAI S P,ZHANG H X,et al.Predictive value of albumin for intravenous immunoglobulin resistance in a large cohort of Kawasaki disease patients[J].Ital J Pediatr,2023,49(1):78. [30] TAN X H,ZHANG X W,WANG X Y,et al.A new model for predicting intravenous immunoglobin-resistant Kawasaki disease in Chongqing:a retrospective study on 5277 patients[J].Sci Rep,2019,9(1):1722. [31] DENG L F,WANG T,DUAN Y,et al.Neutrophil percentage-to-albumin ratio is a potential marker of intravenous immunoglobulin resistance in Kawasaki disease[J].Sci Rep,2024,14(1):15232. [32] GUPTA M,JOHANN-LIANG R,BUSSEL J B,et al.Elevated IgA and IgM anticardiolipin antibodies in acute Kawasaki disease[J].Cardiology,2002,97(4):180-182. [33] WANG Y,CAO Y Y,LI Y,et al.Development of an immunoinflammatory indicator-related dynamic nomogram based on machine learning for the prediction of intravenous immunoglobulin-resistant Kawasaki disease patients[J].Int Immunopharmacol,2024,134:112194. [34] WANG C X,CAO L,MEI W D,et al.The V-shaped curve relationship between fasting plasma glucose and human serum albumin in a large health checkup population in China[J].BMC Endocr Disord,2023,23(1):192. [35] KHAN S R,VAN DER BURGH A C,PEETERS R P,et al.Determinants of serum immunoglobulin levels:a systematic review and meta-analysis[J].Front Immunol,2021,12:664526. [36] RADOSEVICH M,BURNOUF T.Intravenous immunoglobulin G:trends in production methods,quality control and quality assurance[J].Vox Sang,2010,98(1):12-28. [37] BARAHONA AFONSO A F,JOÃO C M P.The production processes and biological effects of intravenous immunoglobulin[J].Biomolecules,2016,6(1):15. [38] SUN Y Y,LIU C X,ZHONG H D,et al.Screening of autoantibodies as biomarkers in the serum of renal cancer patients based on human proteome microarray[J].Acta Biochim Biophys Sin,2022,54(12):1909-1916. [39] YANG Q,YE H,SUN G Y,et al.Human Proteome Microarray identifies autoantibodies to tumor-associated antigens as serological biomarkers for the diagnosis of hepatocellular carcinoma[J].Mol Oncol,2023,17(5):887-900. [40] DUNN S E,PERRY W A,KLEIN S L.Mechanisms and consequences of sex differences in immune responses[J].Nat Rev Nephrol,2024,20(1):37-55. [41] DING B J,LIU L,DAI Y T,et al.Identification and verification of differentially expressed key genes in peripheral blood-derived T cells between chronic immune thrombocytopenia patients and healthy controls[J].Bioengineered,2022,13(5):13587-13595. [42] CAO J J,ZHAN Y X,JI L L,et al.Proinflammatory plasticity towards Th17 paradigm of regulatory T cells consistent with elevated prevalence of TGFBR2 variants in elderly patients with primary immune thrombocytopenia[J].BMC Immunol,2023,24(1):6. [43] LIU H Y,LIU X Y,ZHANG G Y,et al.The short-term predictive value of CD4+ cells for combination therapy with high-dose dexamethasone and immunoglobulin in newly diagnosed primary immune thrombocytopenia patients[J].Thromb Res,2022,218:157-168. [44] LI Q Z,LIU Y,WANG X J,et al.Regulation of Th1/Th2 and Th17/Treg by pDC/mDC imbalance in primary immune thrombocytopenia[J].Exp Biol Med(Maywood),2021,246(15):1688-1697. [45] SEGÚ-VERGÉS C,CAÑO S,CALDERÓN-GÓMEZ E,et al.Systems biology and artificial intelligence analysis highlights the pleiotropic effect of IVIg therapy in autoimmune diseases with a predominant role on B cells and complement system[J].Front Immunol,2022,13:901872. [46] 马亮亮,梁燕,方美云.糖皮质激素受体和热休克蛋白90与原发免疫性血小板减少症患者糖皮质激素抵抗关系的研究[J].中华血液学杂志,2012,33(9):733-737. [47] RIPLEY B J M,ISENBERG D A,LATCHMAN D S.Elevated levels of the 90kDa heat shock protein(hsp90)in sle correlate with levels of IL-6 and autoantibodies to hsp90[J].J Autoimmun,2001,17(4):341-346. [48] SAITO K,KUKITA K,KUTOMI G,et al.Heat shock protein 90 associates with Toll-like receptors 7/9 and mediates self-nucleic acid recognition in SLE[J].Eur J Immunol,2015,45(7):2028-2041. [49] SHUKLA H D,PITHA P M.Role of hsp90 in systemic lupus erythematosus and its clinical relevance[J].Autoimmune Dis,2012,2012:728605. [50] RODRIGUEZ E,GUEVARA J,PAEZ A,et al.The altered expression of inflammation-related molecules and secretion of IL-6 and IL-8 by HUVEC from newborns with maternal inactive systemic lupus erythematosus is modified by estrogens[J].Lupus,2008,17(12):1086-1095. [51] HU S X,XU Q,XIAO W Z,et al.The expression of molecular chaperone HSP90 and IL-6 in patients with systemic lupus erythematosus[J].J Huazhong Univ Sci Technolog Med Sci,2006,26(6):664-666. [52] HU C,YANG J,QI Z P,et al.Heat shock proteins:Biological functions,pathological roles,and therapeutic opportunities[J].MedComm,2022,3(3):e161. [53] GE J,LIU Y.Heat shock protein-70 is elevated in childhood primary immune thrombocytopenia[J].Eur J Med Res,2022,27(1):244. [54] JONES R J,SINGH R K,SHIRAZI F,et al.Intravenous immunoglobulin G suppresses heat shock protein(HSP)-70 expression and enhances the activity of HSP90 and proteasome inhibitors[J].Front Immunol,2020,11:1816. |